-DOCSTART- -X- O
Adenovirus -X- _ O
vectored -X- _ O
vaccines -X- _ O
are -X- _ O
a -X- _ O
highly -X- _ O
effective -X- _ O
strategy -X- _ O
to -X- _ O
induce -X- _ O
cellular -X- _ O
immune -X- _ O
responses -X- _ O
which -X- _ O
are -X- _ O
particularly -X- _ O
effective -X- _ O
against -X- _ O
intracellular -X- _ O
pathogens. -X- _ O
Recombinant -X- _ O
simian -X- _ O
adenovirus -X- _ O
vectors -X- _ O
were -X- _ O
developed -X- _ O
to -X- _ O
circumvent -X- _ O
the -X- _ O
limitations -X- _ O
imposed -X- _ O
by -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
human -X- _ O
adenoviruses -X- _ O
due -X- _ O
to -X- _ O
widespread -X- _ O
seroprevalence -X- _ O
of -X- _ O
neutralising -X- _ O
antibodies. -X- _ O
We -X- _ O
have -X- _ O
constructed -X- _ O
a -X- _ O
replication -X- _ B-Intervention
deficient -X- _ I-Intervention
simian -X- _ I-Intervention
adenovirus-vectored -X- _ I-Intervention
vaccine -X- _ I-Intervention
( -X- _ I-Intervention
ChAdOx2 -X- _ I-Intervention
) -X- _ I-Intervention
expressing -X- _ O
4 -X- _ O
genes -X- _ O
from -X- _ O
the -X- _ O
Mycobacterium -X- _ O
avium -X- _ O
subspecies -X- _ O
paratuberculosis -X- _ O
( -X- _ O
AhpC -X- _ O
, -X- _ O
Gsd -X- _ O
, -X- _ O
p12 -X- _ O
and -X- _ O
mpa -X- _ O
) -X- _ O
. -X- _ O
Safety -X- _ O
and -X- _ O
T-cell -X- _ O
immunogenicity -X- _ O
results -X- _ O
of -X- _ O
the -X- _ O
first -X- _ O
clinical -X- _ O
use -X- _ O
of -X- _ O
the -X- _ O
ChAdOx2 -X- _ B-Intervention
vector -X- _ I-Intervention
are -X- _ O
presented -X- _ O
here. -X- _ O
The -X- _ O
trial -X- _ O
was -X- _ O
conducted -X- _ O
using -X- _ O
a -X- _ O
‘three-plus-three’ -X- _ O
dose -X- _ O
escalation -X- _ O
study -X- _ O
design. -X- _ O
We -X- _ O
demonstrate -X- _ O
the -X- _ O
vaccine -X- _ O
is -X- _ O
safe -X- _ O
, -X- _ O
well -X- _ O
tolerated -X- _ O
and -X- _ O
immunogenic -X- _ O
. -X- _ O

